16 June 2022: Clinical Research
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era
Mevlut Tamer Dincer 1ABCDEF , Zeynep Toker Dincer 2BCE* , Oguz Kagan Bakkaloglu 3CEF , Serkan Feyyaz Yalin 4BE , Sinan Trabulus 1ADE , Aykut Ferhat Celik 3AE , Nurhan Seyahi 1CDE , Mehmet Riza Altiparmak 1ACDEDOI: 10.12659/MSM.936497
Med Sci Monit 2022; 28:e936497
Table 5 Clinical, laboratory, and treatment data of ulcerative colitis patients with or without renal involvement.
| Ulcerative colitis | Patients with renal involvement (n=50) | Control group (n=60) | p |
|---|---|---|---|
| Age in years at diagnosis (mean±SD) | 41.8±15.1 | 37.9±12.2 | 0.231 |
| Follow-up period in years (mean±SD) | 9.7±6.0 | 8.9±6.0 | 0.425 |
| Proctitis | 11 (22.0) | 10 (16.7) | 0.706 |
| Left-sided colitis | 19 (38.0) | 22 (36.7) | |
| Extensive colitis | 20 (40.0) | 28 (46.6) | |
| Active disease | |||
| Endoscopic active | 12 (24.0) | 13 (21.7) | 0.771 |
| Clinical active (UCAI ≥120) | 15 (30.0) | 12 (20.0) | 0.225 |
| Anti-TNF use | 6 (12.0) | 3 (5.0) | 0.182 |
| IBD related surgery | 3 (6.0) | 3 (5.0) | 0.579 |
| Creatinine (mg/dL) | 0.9±0.4 | 0.8±0.2 | |
| e-GFR (mL/min/1.73 m) | 79.0±25.4 | 93.8±21.4 | |
| Uric acid (mg/dL) | 4.6±1.5 | 3.9±1.5 | 0.068 |
| Albumin (g/dL) | 4.1±0.4 | 4.3±0.6 | |
| Hemoglobin (g/dL) | 13.1±1.4 | 13.0±1.7 | 0.904 |
| ESR (mm/h) | 23.1±20.6 | 20.9±19.6 | 0.757 |
| CRP (mg/L) | 6.5±10.3 | 7.0±12.7 | 0.550 |
| CRP – C-reactive protein; ESR – erythrocyte sedimentation rate; e-GFR – estimated glomerular filtration rate; TNF – tumor necrosis factor; UCAI – ulcerative colitis activity index. Significant p values are written in bold. | |||